Table 1.

Prognostic and predictive analyses of BRAF, PIK3CA, PTEN (prognostic significance determined in patients receiving BSC only, predictive significance determined in patients with K-ras wild-type tumors)

Prognostic analysis in BSC patients adj HR (mutant vs. wild-type), [for PTEN, negative vs. present]
BiomarkerOSPFS
BRAF1.47, P = 0.411.52, P = 0.37
PI3KCA1.11, P = 0.651.10, P = 0.66
PTEN1.13, P = 0.700.99, P = 0.98
Predictive analysis in KRAS wild-type subset
adj HR (cetuximab+BSC vs. BSC), interaction P value
OSPFS
BRAF1.39, P = 0.691.18, P = 0.84
PI3KCA0.79, P = 0.630.73, P = 0.50
PTEN0.75, P = 0.612.47, P = 0.088